ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Daewon Pharmaceutical and Yuhan side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

Daewon PharmaceuticalYuhan
studies on the registry49174
open to participants now735
phase 3 studies under way15
reach primary completion within a year110
programswith a study of their own in two years953

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseDaewon PharmaceuticalYuhan
Phase 1

Daewon Pharmaceutical: 3 of its 9 programs at phase 1

  1. DW4421Sphase 1
  2. DW5524phase 1
  3. DW5124phase 1
33%

Yuhan: 45 of its 53 programs at phase 1

  1. AD-1161phase 1
  2. AD-116Aphase 1
  3. AD-118phase 1
  4. AD-230phase 1
  5. PA-111phase 1

and 40 more — sign in to see them all

85%
Phase 2

Daewon Pharmaceutical: 1 of its 9 programs at phase 2

  1. DW4902phase 2
11%

Yuhan: 3 of its 53 programs at phase 2

  1. AD-211phase 2
  2. lesigerceptphase 2
  3. YH32364phase 2
6%
Phase 3

Daewon Pharmaceutical: 5 of its 9 programs at phase 3

  1. DW4421phase 3
  2. DW1026C1phase 3
  3. DW1026C2phase 3
  4. DW5121phase 3
  5. DW5421Bphase 3
56%

Yuhan: 5 of its 53 programs at phase 3

  1. AD-227Bphase 3
  2. AD-233Aphase 3
  3. AD-233Bphase 3
  4. AD-2282phase 3
  5. YHP2401phase 3
9%
Approved, new studies00%00%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Daewon Pharmaceutical1 readouts · 0 phase 3·

Daewon Pharmaceutical, Dec ’26: 1 program whose next study reaches primary completion

  1. DW4421Sphase 1 · Dec 0 · NCT07691242
··········
Yuhan10 readouts · 0 phase 3

Yuhan, Nov ’26: 3 programs whose next study reaches primary completion

  1. AD-234phase 1 · Nov 0 · NCT07717775
  2. AD-2341phase 1 · Nov 0 · NCT07717775
  3. AD-2342phase 1 · Nov 0 · NCT07717775
·

Yuhan, Jan ’27: 2 programs whose next study reaches primary completion

  1. YHP2508Bphase 1 · Jan 26 · NCT07912840
  2. YHR2602phase 1 · Jan 26 · NCT07912840

Yuhan, Feb ’27: 2 programs whose next study reaches primary completion

  1. YHP2508Aphase 1 · Feb 2 · NCT07912827
  2. YHR2601phase 1 · Feb 2 · NCT07912827

Yuhan, Mar ’27: 1 program whose next study reaches primary completion

  1. AD-211phase 2 · Mar 0 · NCT07550231
··

Yuhan, Jun ’27: 2 programs whose next study reaches primary completion

  1. YH32364phase 2 · Jun 0 · NCT06975410
  2. lesigerceptphase 2 · Jun 19 · NCT07415551
····
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 22, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Daewon Pharmaceutical

New programs 0

None

Reached a new phase 1

  • DW4421phase 3 · Oct 23 · Gastroesophageal Reflux

Study stopped 0

None

Primary completion later 0

None

Yuhan

New programs 6

  • YHP2508Aphase 1 · first study · Oct 28
  • YHP2508Bphase 1 · first study · Oct 28
  • YHR2601phase 1 · first study · Oct 28
  • YHR2602phase 1 · first study · Oct 28
  • AD-233Aphase 3 · first study · Sep 7 · Diabetes Mellitus, Type 2
  • AD-233Bphase 3 · first study · Sep 7 · Diabetes Mellitus, Type 2

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Where they overlap

Conditions where at least two of them have programs: 5 in all. A program counts in each condition its studies name most.

ConditionDaewon PharmaceuticalYuhan
Dyslipidemiasboth · compare here

Daewon Pharmaceutical in Dyslipidemias: 1 program

  1. DW5124phase 1

Their studies: Daewon Pharmaceutical’s studies of Dyslipidemias in search

Yuhan in Dyslipidemias: 5 programs

  1. PA-111phase 1
  2. AD-117phase 1
  3. AD-117Aphase 1
  4. AD-231phase 1
  5. PA-111Aphase 1

Their studies: Yuhan’s studies of Dyslipidemias in search

Diabetes Mellitus, Type 2both · compare here

Daewon Pharmaceutical in Diabetes Mellitus, Type 2: 2 programs

  1. DW1026C1phase 3
  2. DW1026C2phase 3

Their studies: Daewon Pharmaceutical’s studies of Diabetes Mellitus, Type 2 in search

Yuhan in Diabetes Mellitus, Type 2: 2 programs

  1. AD-233Aphase 3
  2. AD-233Bphase 3

Their studies: Yuhan’s studies of Diabetes Mellitus, Type 2 in search

Gastroesophageal Refluxboth · compare here

Daewon Pharmaceutical in Gastroesophageal Reflux: 1 program

  1. DW4421phase 3

Their studies: Daewon Pharmaceutical’s studies of Gastroesophageal Reflux in search

Yuhan in Gastroesophageal Reflux: 2 programs

  1. AD-120phase 1
  2. AD-120Aphase 1

Their studies: Yuhan’s studies of Gastroesophageal Reflux in search

Bronchitisboth · compare here

Daewon Pharmaceutical in Bronchitis: 1 program

  1. DW5121phase 3

Their studies: Daewon Pharmaceutical’s studies of Bronchitis in search

Yuhan in Bronchitis: 1 program

  1. YHP2401phase 3

Their studies: Yuhan’s studies of Bronchitis in search

Hypercholesterolemiaboth · compare here

Daewon Pharmaceutical in Hypercholesterolemia: 1 program

  1. DW5421Bphase 3

Their studies: Daewon Pharmaceutical’s studies of Hypercholesterolemia in search

Yuhan in Hypercholesterolemia: 1 program

  1. AD-2282phase 3

Their studies: Yuhan’s studies of Hypercholesterolemia in search

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

No gene two of them both target, among the programs whose target is known.

A target, or a pathogen for a vaccine, known for: Daewon Pharmaceutical 0 of 9 · Yuhan 1 of 53 programs (1 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.